why choose us

First received: June 01, 2023

Clinical Trial: Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Non-Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Squamous Non-

Brief Summary: This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer.The primary endpoint is overall survival and key secondary endpoints include progression free survival.response and safety.

Read more